Phase 2 N=56 CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study
Osteoarthritis
Primary: Hand Function — 5.54; 2.69 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=167 Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) — -0.37; -0.89; -1.03; -1.04 percentage of glycosylated hemoglobin — p=<0.001
Phase 2 N=550 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Overactive Bladder Syndrome (OABS)
Primary: Change From Baseline to Week 8 in the Number of Voids/24 Hours — -1.06; -1.44; -1.78; -2.41 voids/24 hrs.
Phase 2 N=262 A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus — -1.52; -1.29; -1.28; -0.27 percentage of…
Phase 2 N=89 Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Carcinoma of Unknown Primary
Primary: Progression Free Survival — 5.4; 5.3 months
Phase 2 N=32 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 96.88 percentage of participants
Phase 2 N=265 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Glioblastoma
Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328
Phase 2 N=17 A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
Endothelial Dysfunction
Primary: 6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy — 4.6; 4.7; 0.1; 0.2 mm — p=<0.05
Phase 2 N=448 Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia
Coronary Artery Bypass Surgery
Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05
Phase 2 N=48 Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer · Stage IIIA Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: The Primary Endpoint of This Trial is the Proportion of Patients Alive at 1 Year. Phase II Patients Only. — 0.73 proportion of Participants
Phase 2 N=28 Study of Sorafenib/Cetuximab in Head and Neck Cancer
Squamous Cell Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Sorafenib Administered With Cetuximab (400 mg/m2 Loading Dose Followed by 250 mg/m2 Weekly) — 400 mg
Phase 2 N=230 INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
AMD · Wet AMD · Age-Related Macular Degeneration
Primary: Number of Lucentis® Injections Up To And Including Week 52 — 2.64; 2.44; 3.73 Injections
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
Phase 2 N=60 Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Change in ALS Functional Rating Scale - Revised (ALSFRS-R) — -0.905; -0.983; -0.743 scores on a scale
Phase 2 N=43 Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…